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Stem cells are characterized by their capacity to self renew and differentiate into 
progressively restricted cells that ultimately become limited to a specific cell fate. The two 
broad types of mammalian stem cells are: embryonic stem cells and adult stem cells. 
Embryonic stem cells (ESC) are mostly derived from the undifferentiated inner mass cells of a 
blastocyst. These cells give rise during development of the embryo to all derivatives of the 
three primary germ layers: ectoderm, endoderm and mesoderm. They do not contribute to the 
extra-embryonic membranes or the placenta. Ex-vivo, they can be cultured for extended 
periods of time and under the appropriate conditions, they can be also directed to differentiate 
into many specialized types of cells. These particular features are being exploited to use ESC as 
starting material for treatment of degenerative diseases and replacement of damaged organs. 
Although their potential is great, the promise of ESC-derived therapies will be unfulfilled 
unless several challenges are overcome. For example, the quite small production of ESC-
derived cells obtained or the active immune rejection of the ESC-derived graft. 
Unlike embryonic stem cells, the adult stem cells are already partially specialized. They 
have been found in most self-renewing tissues, including the skin, the brain, the intestinal 
epithelium and the hematopoietic system and have the primary role of maintaining and 
repairing the tissue in which they are found. They are located deep within organs in 
specialized areas known as the “stem cell niche” (Scadden, 2006). This microenvironment 
allows for their survival, self renewal, regulated proliferation and maintenance of their 
quiescence for long periods of time until the moment in which they are activated. Ex vivo, 
however, the capacity of stem cells to self-renew is limited, they exhibit poor survival and 
consequently their numbers sharply declines during experimental manipulation. 
One of the more intriguing but highly debated areas of stem cell biology was the phenomenon 
described as plasticity or transdifferentiation. Numerous reports expressed opposing views 
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about this ability of stem cells to cross organ/tissue boundaries. These discrepancies have now 
been mostly passed over by current research showing that cell populations of one lineage 
might produce cells from other lineages by changing gene expression in response to micro-
environmental cues (Jang and Sharkis, 2005; Theise, 2010). 
Owing to their unique characteristic of plasticity, self-renewal capacity and potential to 
generate functional cell types, stem cells are particularly attractive for developing 
therapeutic settings that range from drug discovery protocols to cell transplantation and 
regenerative therapies. Nevertheless, several challenges including the need to identify the 
signals that influence the stem cell fate decisions and the application of this information 
towards the design of stem cell bioprocesses have to be overcome to accomplish the 
transition from fundamental science to functional technologies. 
1.1 Hematopoietic stem cells 
Hematopoietic stem cells (HSC) are probably the best characterized adult stem cell and 
often serve as a paradigm for other stem cells. Even though no morphological criteria to 
unequivocally identify such cells exist, HSC have been proven to be invaluable in the clinic. 
They are the only stem cells used routinely in cell based therapies, to treat numerous 
hematologic and non-hematologic malignancies as well as a range of both inherited and 
acquired diseases. This is typically due i) to the availability of a straight forward purification 
protocols using cell surface antigen selection and ii) to the possibility to perform 
reconstitution assays that rely on their clonal ability to reconstitute the entire hematopoietic 
system following transplantation into myeloablated recipients (Fig. 1). The same cell surface 
antigens, however, do not always conform to the same stem cell functional phenotype 
(Simonnet et al., 2009) and therefore the transplantation procedure constitutes undoubtedly 
the “gold standard” method for proving that a cell is indeed an HSC. 
 
Fig. 1. A diagrammatic representation of a stem cell in its micro-environment and one stem cell 
induced to move out of the niche where it will undergo development. Following BM removal 
and cell surface antigen selection (1), cells are cultured in vitro and infused in a myeloablated 
mouse. Several weeks after (2), blood cells are regenerated in the transplanted mouse. 
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To maintain the steady-state of the stem cell compartment and to allow the regeneration of 
hematopoietic cells after transplantation or after hematopoietic injury, HSC divide 
asymmetrically or symmetrically. In an asymmetric self-renewing division, the two daughter 
cells adopt different fates, resulting in only one cell maintaining stem-cell properties. The 
symmetric self-renewing division refers to the process whereby both daughter cells retain stem 
cell properties. This type of cell division expands the stem-cell pool and is therefore critical for 
sustaining the HSC compartment and thus is a requirement for lifelong hematopoiesis. 
The HSC fate decisions are dependent on concomitantly intrinsic HSC fate determinants and 
extrinsic signals delivered by the bone marrow (BM) niches were HSC resides. These niches 
are small cavities formed by heterogeneous types of cells, named stroma, that are positioned 
close to the BM longitudinal axis of the femur with more differentiated cells disposed in a 
graduated manner as the central longitudinal axis of the bone is approached. The 
attachment of HSC to the stroma via a network of adhesion molecules provide an 
environment that optimally balances signals that control self-renewal, proliferation and 
differentiation. Under normal physiological conditions, HSC are kept in a relatively low 
proliferative, quiescent state, protecting them from stress and preventing their depletion 
due to excessive proliferation (Jang and Sharkis, 2007). Recent data imply that these areas 
where HSC reside are hypoxic (Parmar et al., 2007). 
To take advantage of the HSC plasticity capacities for therapeutic use, HSC may be 
withdrawn from their original niches, and placed on a novel non-hematopoietic 
environment. Once located in this novel medium, the reprogramming of the cell genome 
occurs and directs and/or contributes to their conversion into unrelated cell types (Fig. 2). 
The unexpected flexibility of HSC to produce non-hematopoietic cells was described for 
several cells/tissues (Quesenberry et al., 2010) including liver cells (Almeida-Porada et al., 
2010; Jang et al., 2004), neurones (Mezey et al., 2000), lung epithelial (Abe et al., 2003) or 
connective tissues (Ogawa et al., 2010). 
 
Fig. 2. A schematic representation of HSC plasticity. Hematopoietic cell are removed from the 
femoral bone (1) and the HSC-enriched population is cultured in vitro. Following an optional 
genetic modification, cells may be used to generate in vivo non-hematopoietic cell types. 
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The development of HSC-based therapies however, is to some extent prevented by the 
scarce representation of HSC in the BM and their finite lifespan ex vivo. Increasing their 
utilisation needs enhancement of hematopoietic stem cells availability or de novo generation 
of HSC. This presumes i) the development of robust methods to efficiently control HSC 
regulatory processes; ii) the therapeutic in vivo or in vitro expansion of HSC number and iii) 
the utilisation of optimized protocols  to generate available HSC from ESC or IPSC. 
2. Physiological pathways involved in the regulation of stem cells  
HSC fate decisions are supported by the orchestration of several pathways such as Wnt, 
Notch and Hedgehog pathways that critically balance cell cycling and quiescence, leading to 
proliferation and apoptosis, self-renewal or differentiation (Fig. 3). The ultimate decision is 
dependent on hundreds of inputs including concentrations of different growth factors, 
cytokines, hormones, oxygen levels that must be integrated to subsequently activate these 
different signal transduction cascades. Understanding their regulation might led to the 
effective and more spread out utilization of HSC in clinical settings. The most relevant 
aspects of these pathways are briefly resumed below. 
 
Fig. 3. A schematic representation of signaling pathways collectively influencing stem cell 
fate. 
2.1 The hedgehog (Hh) signaling 
In adult tissues, Hh signaling is involved in the maintenance of stem cells, regeneration and 
tissue repair where it governs processes like cell proliferation, cell renewal and 
differentiation. The three Hh ligand homologues: Sonic Hh, Indian Hh, and Desert Hh bind 
interchangeably the two related twelve-pass membrane Patched (Ptc) receptors. They relieve 
the inhibition of smoothened (SMO), a serpentine receptor resembling G protein–coupled 
receptors allowing activation of a family of zinc-finger transcription factors called GLI and 
the modification of the expression Hh target genes (Kasper et al., 2009). 
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The role of Hh signaling in HSC is controversial. Bhardwaj et al provided evidence for a role of 
Hh signaling in HSC (Bhardwaj et al., 2001). In this study, suppression of Hh signaling 
inhibited proliferation of HSC and addition of soluble SHh induced expansion of 
hematopoietic repopulating cells (Bhardwaj et al., 2001). More recent reports confirmed that 
suppression of the Hh pathway leads to a severe defect in HSC functions (Merchant et al., 
2010; Trowbridge et al., 2006) whereas others reported that this pathway can be dispensable 
for HSC biology (Gao et al., 2009; Hofmann et al., 2009). In Ptc1+/−mice, which have increased 
Hh activity, activation of the Hh signaling pathway induces expansion of primitive blood cells 
under homeostatic conditions. However, when HSC are challenged to regenerate the blood 
system, persistent Hh activation leads to HSC exhaustion (Trowbridge et al., 2006). 
Furthermore, Indian Hh gene transfer can confer enhanced hematopoietic support ability to 
BM stromal cells, suggesting that it is involved in the interaction between HSC and the stromal 
cells. This leads to an increase in proliferation and repopulating capacity of primitive 
hematopoietic cells (Kobune et al., 2004). These results suggest a role for Hh signaling in 
balancing homeostasis and regeneration in vivo. In contrast, other reports show that Hh 
signaling is dispensable for adult HSC functions (Gao et al., 2009; Hofmann et al., 2009). In 
these studies conditional deletion of SMO, the only non redundant component of the Hh 
cascade, or pharmacologic inhibition of Hh signaling have no apparent effect on adult 
hematopoietic, including peripheral blood count, number or cell cycle status of stem or 
progenitor cells, hematopoietic colony-forming potential or long-term repopulating activity in 
in vivo assays. In agreement with this notion, genome-wide transcriptome analysis revealed 
that silencing the Hh signaling does not significantly alter the HSC-specific gene expression 
‘‘signature.’’ Taken together, these conflicting data suggest that Hh signaling may influence 
HSC through more complex networks such as cell-niche interactions. 
2.2 Fibroblast growth factor (FGF) signaling 
FGF belongs to a family of heparin-binding polypeptides that shows multiple functions, 
including effects on cell proliferation, differentiation and survival (Baird, 1994). Twenty-four 
members of the FGF family have been identified in human and mice. FGFs bind and activate 
their cognate FGFRs that are encoded by four genes (FGFR1– 4). This results in receptor 
dimerization, tyrosine kinase autophosphorylation, and recruitment of signaling complexes. 
The FGF signal transduction proceeds by one, or a combination, of three main pathways: 
Ras/mitogen-activated protein kinase (MAPK) signaling; planar cell polarity/calcium;  
phosphoinotitide-3-kinase (PI3K)/Akt (extensively reviewed by Bottcher and Niehrs, 2005). 
Both FGF-1 and FGF-2 support HSC expansion when unfractionated mouse BM cells are 
cultured in serum-free medium (de Haan et al., 2003; Yeoh et al., 2006). Crcareva et al. 
confirmed that FGF-1 stimulates ex-vivo expansion of HSC (Crcareva et al., 2005). Conditional 
derivatives of FGFR-1 have also been used to support short-term HSC expansion and long-term 
HSC survival (Weinreich et al., 2006). This factor seems to also support ex vivo expansion of 
murine and human HSC in combination with other cytokines, i.e stem cell factor [SCF], 
thrombopoietin [TPO], insulin-like growth factor-2 [IGF-2], and fibroblast growth factor-1 [FGF-
1] (Zhang and Lodish, 2005). Moreover, a recent study showed that addition of SCF, TPO, and 
FGF-1 to a mesenchymal stem cells (MSC) culture stimulates proliferation, maintenance of 
primitive immunophenotype, and expansion of CFU-initiating cells. This supports the notion 
that expansion of HSC requires complex stimulation of different signal cascades activated by 
soluble growth factors as well as adhesion proteins (Walenda et al., 2011). 
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2.3 Notch signaling 
The Notch pathway is also an evolutionarily conserved mechanism that plays a 
fundamental role in regulating cell-fate decisions (Bolos et al., 2007). Four types of Notch 
receptors (Notch 1-4) and five Notch ligands (Jagged 1 and 2, Delta 1, 3 and 4) have been 
identified in vertebrates. Notch ligands are single-pass transmembrane proteins consisting 
of multiple EGF-like repeats and a characteristic DSL (Delta, Serrate, and LAG-2) domain 
(see for review Ohishi et al., 2003; Shimizu et al., 2000). One characteristic of this signaling 
pathway is the dual role of Notch as both a transmembrane receptor and a transcription 
factor in a system where no second messengers are used (Matsuno et al., 1995). Notch can 
have opposite functions in different self-renewing organs indicating that the outcome of 
Notch activation depends to a great extent on the cell context and the specific growth factors 
present in the microenvironment. For example, activation of Notch1 by Delta ligands 1 and 
4 is required for inducing T-cell and inhibiting B-cell differentiation whereas Notch2 
activation by Jagged1, and possibly Delta1, acts on HSC (Han et al., 2002; Radtke et al., 1999; 
Varnum-Finney et al., 2011).  
A role for Notch in hematopoietic was initially suggested by detection of the human Notch1 
gene in CD34+ or lineage (Lin)-CD34+ hematopoietic  cells (Milner et al., 1994). Transduction 
of murine HSC with a retrovirus expressing a constitutively active form of Notch1 induced 
the emergence of an immortalized pluripotent cytokine-dependent cell line capable of both 
myeloid and lymphoid repopulation in vivo, thereby demonstrating a role for Notch in HSC 
self-renewal (Varnum-Finney et al., 2000). Similar results were obtained using an 
immobilized form of the Notch ligand Delta-1 since incubation of murine HSC with 
immobilized Delta-1 and cytokines led to a several-log expansion of cells capable of short-
term in vivo reconstitution (Varnum-Finney et al., 2003). 
In contrast to the murine studies, only a modest or no increase in the progenitor numbers 
was achieved by expressing activated Notch-1 in human CD34+ cord blood cells (Carlesso et 
al., 1999; Chadwick et al., 2007) or by incubation with Delta-1 (Jaleco et al., 2001), Delta-4 
(Lauret et al., 2004) or Jagged-1 (Karanu et al., 2000; Karanu et al., 2001; Walker et al., 1999). 
This contrast with other reports showing that incubation of human cord blood cells with the 
immobilized Delta-1 combined with fibronectin fragments and cytokines induce a 100-fold 
increase in the number of CD34+ cells compare to controls (Ohishi et al., 2002) and a 16-fold 
increase in SCID Repopulating Cells (SRC) number compared to uncultured cells. In vivo 
transplanted cells persisted 9 weeks post-transplantation and in secondary recipients, 
suggesting the presence of both long-term and short-term repopulating cells following 
culture of human cord blood cells on Delta-1 ligand (Delaney et al., 2010). The SRC 
enhancement by relatively low density of immobilized ligand and the preference to promote 
differentiation toward the T-cell lineage at higher ligand density revealed important ligand 
dose-dependent effects of Notch signaling (Delaney et al., 2005). 
The engineered Notch ligand approach for ex vivo expansion of human cord blood cells is 
now under clinical investigation (http://clinicaltrials.gov/ct2/show/record/ 
NCT00343798). In this phase 1 clinical trial, patients undergoing a myeloablative double 
cord blood transplantation are receiving one non-manipulated cord blood unit along with a 
second cord blood unit that has undergone Notch-mediated ex vivo expansion. These cells 
were safely infused and led to a significant reduction in the time needed for neutrophil 
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recovery (16 days in patients receiving the expanded unit, compared to 26 days in patients 
of the concurrent cohort). Similarly, preliminary evaluation of time needed for platelet 
recovery compared favourably in those patient receiving the expanded cell product 
compared with those receiving non-manipulated cells (Dahlberg et al., 2011). In addition, 
comparable overall survival and graft-versus-host disease risk of patient receiving non-
manipulated cells was observed within the average follow-up of 354 days. The expanded 
cell population may also have retained long-term repopulating capacities as two patients 
display in vivo persistence of cultured donor cells. The lack of in vivo persistence in the 
remaining patients may either be due to loss of stem cell self-renewal capacity during ex vivo 
culture or to immune mediated rejection. Indeed, it has been well documented that in most 
of the patients who received two non-manipulated cord blood units for transplantation, 
only one contributes to persistent long-term engraftment. The mechanism responsible for 
this single donor dominance remains yet to be defined. Larger phase II/III studies are 
required to evaluate whether co-infusion of this expanded cell product decreases the 
occurrence of serious infection, improves survival, or affects duration of hospital stay 
(Delaney et al., 2010). 
2.4 The transforming growth factor beta (TGF) superfamily 
The TGF superfamily consist of a large collection of secreted proteins that regulate cell 
growth, differentiation, apoptosis, cellular homeostasis, and other functions in both the 
adult organism and the developing embryo. The more than 30 TGF family ligands are 
organized into three subgroups (reviewed in (Lyssiotis et al., 2011)). The TGF (which 
comprises SMAD and Activin/Nodal ligands), bone morphogenetic protein (BMP), and the 
growth differentiation factors (GDF). The TGF signaling leads to the phosphorylation of 
Smads by activated receptors resulting in their partnering with the common signaling 
transducer Smad4, and translocation to the nucleus. Once activated, Smads regulate diverse 
biological effects by partnering with transcription factors resulting in cell-state specific 
modulation of transcription (Kaivo-Oja et al., 2003). 
A significant number of studies have demonstrated that TGF inhibits proliferation of both 
murine and human HSC in vitro. It was suggest that TGF induces quiescence in HSC since 
its neutralization was showed to release early hematopoietic progenitors cells from 
quiescence (Hatzfeld et al., 1991; Yamazaki et al., 2009). In agreement with studies 
performed in vitro, injection of TGF1 into the femoral artery of mice effectively inhibits 
proliferation of multipotent hematopoietic progenitors in the BM, establishing an inhibitory 
role of TGF1 also in vivo (Goey et al., 1989). Despite a key role in vitro, TGFdid not seem 
to provide the necessary signals that maintain quiescence and the stem cell pool in vivo  
(Larsson et al., 2005). 
To block the entire Smad signaling pathway, the Smad7 was overexpressed in murine HSC 
using a retroviral gene transfer approach. Forced expression of Smad7 significantly 
increased the self-renewal capacity of HSC in vivo (Blank et al., 2006). In a similar approach 
using human hematopoietic cells, overexpression of Smad7 resulted in a shift from 
lymphoid-dominant engraftment toward the myeloid lineage, and an increase of the 
myeloid-committed clonogenic progenitor frequency in NOD-SCID mice (Chadwick et al., 
2005). Instead, Smad4-deficient HSC displayed a significantly reduced repopulative capacity 
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of primary and secondary recipients (Karlsson et al., 2007). Because overexpression of 
Smad7 versus deletion of Smad4 would be anticipated to yield similar hematopoietic 
phenotypes, it is conceivable that Smad4 functions as a positive regulator of self-renewal 
independently of its role as a central mediator of the canonical Smad pathway. In the 
context of adult hematopoiesis, a high concentration of BMP-4 was shown to promote 
maintenance of human cord blood cells in vitro, while lower concentration of BMP4, BMP2 
and BMP7 induced proliferation and differentiation of HSC (Bhatia et al., 1999).  
2.5 Wingless-type (Wnt) pathway 
Wnt proteins are secreted morphogens necessaries for basic developmental processes, such 
as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell 
division, in many different species and organs (Bejsovec, 2005; Moon et al., 2004). Wnt 
proteins bind to cell surface receptors of the Frizzled family which can translocate the 
signals to the nucleus and function as transcriptional activators through intracellular -
catenin. Different Wnt pathways are known but their clear separation and their 
independence remain controversial. There is one canonical pathway that acts on the stability 
of -catenin and interacts with T cell transcription factors in the nucleus. There are many 
non-canonical pathways like the PCP and Wnt/Calcium pathways. The most distinctive 
differences between the canonical and non-canonical pathways include the specific ligands 
activating each pathway, ß-Catenin, LRP5/6 co-receptor, and Dsh-DEP domain 
independence, respectively, and the ability of the non-canonical pathways to inhibit the 
canonical pathway. Ligands that activate the non-canonical pathways are Wnt4, Wnt5a, and 
Wnt11.  
Recent evidence based on genetic models suggests that canonical Wnt signaling, regulates 
HSC self-renewal. Active -catenin promotes HSC proliferation and inhibits differentiation 
(Kirstetter et al., 2006; Scheller et al., 2006) whereas deficiency in -catenin inhibits HSC self-
renewal (Cobas et al., 2004; Luis et al., 2009; Zhao et al., 2007). Moreover, purified Wnt3a 
treatment of adult HSC increases self-renewal of murine HSC, as determined by in vivo 
reconstituting assays (Willert et al., 2003) and of human Lin-CD34+ cells as measured by 
immunophenotype and colony assays (Van Den Berg et al., 1998).  
The role of the non-canonical pathways is not well defined, but surprisingly, their activation 
and consequently inhibition of the canonical pathway, appears also to be able to expand 
HSC. Murdoch et al. demonstrated that injecting mice with Wnt5a conditioned media prior 
to transplant of human umbilical cord blood cells increased engraftment more than 3-fold 
(Murdoch et al., 2003). Furthermore, culturing Lin-Sca-1+c-Kit+ (LSK) cells with recombinant 
murine Wnt5a resulted in an enhancement of hematopoietic reconstitution in a BM 
transplant assay. Wnt5a seems to activate the non-canonical signaling pathways leading to a 
3.5- fold more HSC in G0 phase (Nemeth et al., 2007).  
Overexpression of Wnt4 led to a modest increase in HSC frequency as measured by phenotype 
and limiting dilution transplant assays and Wnt4-/- mice showed decreased frequencies of 
HSC in BM.  Similar to the results obtained using Wnt5a, overexpression of Wnt4 led to an 
increase in the percentage of HSC in G0 (Louis et al., 2008). Whether Wnt4 and Wnt5a inhibit 
the canonical pathway in a similar fashion remains to be elucidated. These results show the 
importance of a balanced regulation of these two overlapping Wnt signaling pathways. 
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2.6 Cross-talk between these pathways 
The individual contribution of these pathways to the hematopoietic development of HSC 
have been extensively addressed (Cerdan and Bhatia, 2010). However, there are many 
potential intersections along them and therefore the impact of their collective contribution 
towards influencing the fate of HSC should be carefully considered. Some of these 
intersection points are resumed below. 
Ducan et al. provide a model for how HSC may integrate multiple signals to maintain 
the stem cell state. They showed that although the proliferation and survival of HSC 
exposed to Wnt proteins seem unaffected when Notch signaling is impaired, their ability 
to remain undifferentiated is substantially altered (Duncan et al., 2005). These results 
demonstrated that the Notch pathway is imperative in maintaining HSC in an 
undifferentiated state. These findings do not preclude the possibility that a stronger Wnt 
signal, such as activated -catenin, may be able to overcome the consequences of loss of 
Notch signaling. Moreover, Wnt3a regulates the expression of established Notch target 
genes (Duncan et al., 2005) and the inhibition of GSK-3, a downstream target of Wnt 
signaling that affects HSC fate through mechanisms involving both Wnt and Notch 
target genes (Trowbridge et al., 2006). These findings suggest that these pathways could 
play a role in HSC self renewal using a common network of regulatory circuits with Wnt 
enhancing proliferation and survival, and Notch preventing differentiation (Blank et al., 
2008). 
Furthermore, there is substantial evidence for the cross-talk between the Wnt signaling 
pathway and FGFs and TGF-b by means of the association between Smad4 and Hox 
proteins. Homeobox (hox) genes encode transcription factors that function as regulators of 
hematopoiesis and are frequently dysregulated in human leukemia, particularly acute 
myeloid leukemia (Kroon et al., 1998). Recently, Wang et al described a mechanism whereby 
TGF-ǃ/BMP inhibited the BM transformation capacity of HoxA9 and HoxA9-Nup98 fusion 
protein through a Smad4-dependent mechanism. Accordingly, Smad4 was shown to interact 
directly with HoxA9 and Nup98-HoxA9 fusion protein, thus precluding their DNA binding 
capacity and subsequent transcriptional activity (Wang et al., 2006). Smad4 also seems to 
participate in other signaling cascades such as Wnt or Notch (Itoh et al., 2004; Labbe et al., 
2000). 
These studies show the high interdependence between the different pathways, and the 
impact of their collective contribution on HSC self-renewal. This should be carefully 
considered when trying to expand HSC for clinical purposes. 
2.7 Epigenetic control and HSC self-renewal 
Epigenetic modifications, in addition to the intracellular pathways described in the previous 
section also play an essential role in regulating self-renewal, differentiation and tissue 
development. They induce gene expression regulation and can be grouped into three main 
categories: i) DNA methylation, ii) Histone modifications and iii) Nucleosome positioning. 
Recent studies suggest that epigenetic mechanisms contribute to establish the HSC unique 
characteristics. The following is a description of some of these examples. 
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2.7.1 Methylation of DNA 
The most widely studied epigenetic modification in humans is cytosine methylation. DNA 
methylation occurs almost exclusively in the context of CpG dinucleotides that tend to 
cluster in regions called CpG islands. A group of enzymes, the DNA methyltransferases 
(DNMTs) tightly regulate both the initiation and maintenance of these methyl marks. DNA 
methylation can inhibit gene expression by various mechanisms. Methylated DNA can 
promote the recruitment of methyl-CpG-binding domain proteins which in turn recruit 
histone-modifying and chromatin-remodeling complexes to methylated sites. DNA 
methylation can also directly inhibit transcription by precluding the recruitment of DNA 
binding proteins from their target sites. In contrast, unmethylated CpG islands generate a 
chromatin structure favorable for gene expression (Portela and Esteller, 2010). 
Methylation is controlled by at least 3 DNMTs: DNMT3a and DNMT3b for de novo 
methylation and DNMT1 for methylation maintenance. Conditionally disruption of Dnmt3a, 
Dnmt3b, or both Dnmt3a and Dnmt3b (Dnmt3a/Dnmt3b) showed that Dnmt3a and Dnmt3b 
function as de novo DNA methyltransferases during differentiation of hematopoietic cells. 
Unexpectedly, in vitro colony assays showed that both myeloid and lymphoid lineage 
differentiation potentials were maintained in Dnmt3a-, Dnmt3b-, and Dnmt3a/Dnmt3b-
deficient HSC. However, Dnmt3a/Dnmt3b-deficient HSC, but not Dnmt3a- or Dnmt3b-
deficient HSC, were incapable of long-term reconstitution in transplantation assays, 
suggesting a role for DNA methylation by Dnmt3a and Dnmt3b in HSC self-renewal 
(Tadokoro et al., 2007). 
Conditional disruption of Dnmt1 in the mouse hematopoietic system revealed defects in 
self-renewal, niche retention, and in the ability of cells to give rise to multilineage 
hematopoiesis. Loss of Dnmt1 had specific impact on myeloid progenitor cells, causing 
enhanced cell cycling and inappropriate expression of mature lineage genes (Trowbridge et 
al., 2009). Consistent with these results, Broske et al. showed that Dnmt1 is essential for HSC 
self-renewal but dispensable for homing, cell cycle control and suppression of apoptosis but 
also implicated Dnmt1 in lymphoid differentiation (Broske et al., 2009). 
2.7.2 Histone modifications and nucleosome positioning  
A nucleosome is a histone octamer composed by a histone H3-H4 tetramer and two H2A-
H2B dimers, around which DNA, 147 base pairs in length, is wrapped in 1.75 superhelical 
turns. Nucleosomes are connected by the so-called linker DNA and the histone H1. Histones 
post-transcriptional modifications, including acetylation, methylation, phosphorylation, 
ubiquitination, SUMOylation and ADP-ribosylation, occur predominantly in histone tails. 
They have important roles in transcriptional regulation as they can provide either an ON or 
OFF signature which result in the tight regulation of gene expression but display also 
important roles in DNA repair, DNA replication, alternative splicing and chromosome 
condensation. Nucleosomes act as barriers to transcription. They block access of activators 
and transcription factors to their sites on DNA and inhibit the elongation of the transcripts. 
The packaging of DNA into nucleosomes appears to affect all stages of transcription, 
thereby regulating gene expression. Nucleosome positioning plays also an important role in 
shaping the methylation landscape (Portela and Esteller, 2010). 
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Polycomb group (PcG) and Trithorax group (TrxG) proteins have emerged as key players 
in gene regulation and are thought to function coordinately to orchestrate DNA 
accessibility. These epigenetic regulators act antagonistically to either promote (TrxG) or 
repress (PcG) transcription through regulation of specific amino acid modifications in 
histones. It is not known how the PcG and TrxG proteins switch and balance between 
transcriptionally silenced heterochromatin (for example, enriched in histone H3 lysine 27 
trimethylation, H3K27me3) and transcriptionally competent euchromatin (for example, 
enriched in histone H3 lysine 4 trimethylation, H3K4me3), respectively, during 
development. 
In vertebrates, polycomb group proteins participate mainly in two complexes, Polycomb 
Repressive Complex (PRC) 1 and PRC2. Probably the best example of a chromatin-
associated factor involved in self-renewal is BMI1, which is a component of PRC1. BMI1 is 
expressed in HSC and its expression decreases upon differentiation towards myeloid or 
erythroid cells, but is retained within the lymphoid compartments. Upon deletion of BMI1, 
no changes in the number of HSC in the fetal liver were observed, but in postnatal BMI1-/- 
mice, the number of HSC was markedly reduced. Targeted deletion of BMI1 in murine HSC 
impaired their competitive repopulation capacity (Park et al., 2003). In vitro, BMI1-/- HSC 
proliferated poorly and displayed an accelerated loss of multilineage differentiation 
potential and overexpression of BMI1 enhanced the self-renewal of HSC and enhanced their 
engraftment potential (Iwama et al., 2004).  
Overexpression of BMI1 in cord blood CD34+ cells resulted in stem cell maintenance. After 
an in vitro culture period of 10 days, BMI1-overexpressing cells display a much better 
engraftment in NOD-SCID mice. Although the mechanisms involved remain to be 
elucidated, it was observed in single-cell assays that the percentage of CD34+/CD38- HSC 
undergoing apoptosis was reduced, whereas the percentage of quiescent HSC not 
undergoing cell cycle progression was increased upon BMI1 overexpression (Rizo et al., 
2008). Lentiviral downmodulation of BMI1 in human cord blood CD34+ cells impaired long-
term expansion, progenitor-forming capacity and stem cell frequencies, both in cytokine-
driven liquid cultures and in BM stromal cocultures. This was associated with higher 
expression of p14ARF and p16INK4A and enhanced apoptosis, which coincided with 
increased levels of intracellular reactive oxygen species (ROS) and reduced FOXO3A 
expression (Rizo et al., 2008). 
Another example of a chromatin-associated factor involved in self-renewal is the mixed 
lineage leukemia (MLL) protein, which encodes a trithorax-group chromatin regulator. 
Using Mll-deficient ESC to generate chimeras, Ernst et al. showed a cell-intrinsic 
requirement for MLL in the generation of lymphoid and myeloid populations in adult 
animals (Ernst et al., 2004). Moreover, MLL is often fused to the AF9 protein in leukemia 
and have been reported to impart leukaemia stem cell properties on committed 
hematopoietic progenitors. The leukemia stem cells generated can maintain the global 
identity of the progenitor from which they arose while activating a limited stem-cell- or 
self-renewal-associated programme (Krivtsov et al., 2006). Moreover, this MLL-AF9 
fusion drives high-level expression of multiple Hox genes and can overcome Bmi1-
deficiency to establish leukemic stem cells (Smith et al., 2011).  
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The studies described in this section establish that epigenetic alterations can modulate the 
self-renewal process. Epigenetic state in stem cells can be stably heritable or can be erased 
(partly or completely) by cell division. These changes might facilitate the transition of a 
progenitor cell to a self-renewing stem cell, or might prompt a stem cell to differentiate, 
divide or lose its ability to self-renew. 
3. Compounds modifying HSC capacities 
As described in the previous section, the strategy for stem-cell expansion involves activation 
of regulators that encourage HSC self-renewal and/or inhibition of pathways that mediate, 
differentiation or apoptosis by using primarily genetic modification approaches. An 
alternative strategy might imply pharmacological intervention by using a variety of small 
molecules. The term “small molecule” refers to a molecular entity that interacts with one or 
more molecular targets and effects a change in biological state while having minimal side 
effects. These small molecules, defined by a known structure, may be chemicals, proteins, 
small interfering RNAs or antibodies. Some of the most effective compounds for ex vivo 
maintaining or expanding HSC are reviewed below. 
3.1 Regulation by cytokines 
Cytokines are secreted proteins that regulate many aspects of hematopoiesis, such as, 
immune responses and inflammation. Numerous attempts have been made to use classic 
hematopoietic cytokines for the purpose of expanding HSC in vitro. Many interleukins, 
including interleukin (IL)-3, IL-6, and IL-11, Flt-3 ligand, TPO and SCF have extensively 
been investigated. In most cases, efforts to expand HSC have failed because of 
differentiation of HSC and subsequent loss of their reconstitution capacity. The combination 
of these molecules has however allowed maintaining HSC in culture for several days 
allowing their use in protocols for gene or cell therapies. Here we describe some examples of 
cytokines that were used to maintain HSC levels in culture. 
3.1.1 Thrombopoietin (TPO) 
TPO, acting through its receptor c-MPL, is the chief cytokine that regulates 
megakaryocyte production. However, several studies suggest that TPO can act to increase 
the ex-vivo expansion of HSC (Sitnicka et al., 1996). This effect was far more effective when 
used in combination with other cytokines including SCF, fms-like tyrosine kinase 3 ligand 
(FLT3-L), IL-3 or IL-6. Human cord blood cells expanded with this cytokine cocktail were 
shown to provide good short- and long-term platelet recovery and lymphomyeloid 
reconstitution in NOD-SCID mice (Ohmizono et al., 1997; Pineault et al., 2010). Further, a 
non peptidyl molecule agonist of c-MPL, NR-101, was found to be more efficient than 
TPO in expanding HSC. Indeed, 7 days culture of human cord blood CD34+ or 
CD34+CD38-, treated with NR-101 induced a 2-fold increase in their number compare to 
TPO and a 2.9-fold or 2.3-fold increase in SRC numbers compared to freshly isolated 
CD34+ cells or TPO-expanded cells respectively. As it was not more efficient than TPO in 
inducing megakaryocyte expansion, its effect seemed to be HSC specific. NR-101 
treatment appeared to persistently activate STAT5 and to induce a long-term 
accumulation of HIF-1ǂ (Nishino et al., 2009).  
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3.1.2 Angiopoietin-like 5 (ANGPLT5) and insulin-like growth factor binding protein 2 
(IGFBP2) 
Soluble growth factors, such as ANGPLT5 and IGFBP2, produced by the endothelium may 
enhance HSC expansion ex vivo when used with conventional cytokines. Although the 
addition of ANGPLT5 and/or IGFBP2 to a 10 days-human CD133+ cord blood cells culture 
has no effect upon the total nucleated cells number in vitro, it significantly enhances in vivo 
repopulation of NOD-SCID mice 2 months post-transplantation as well as secondary 
transplantation (Zhang et al., 2008a). These results were confirmed recently using human 
cord blood CD34+CD133+ cells cultured for 10 days in the presence of IGFBP2 and 
ANGPLT5. Expanded cells were shown to be capable of long-term multi-lineage and multi-
site hematopoiesis in serial reconstitution in NSG mice (Drake et al., 2011). 
3.1.3 Pleiotropin (Ptn) 
Pleiotropin, which have mitogenic and angiogenic activities, has been found to be essential 
for maintenance of murine HSC. Mice transplanted with LSK CD34- cells treated with Ptn 
and a standard cocktail of cytokines showed 6-fold increase in HSC frequency compared to 
cells treated with cytokines alone. In vivo, systemic administration of Ptn was found to 
increase the number of BM LSK cells both in irradiated and nonirradiated mice, suggesting a 
role for this factor in the in vivo regeneration of HSC. Treatment of human cord blood Lin-
CD34+CD38- cells with Ptn for 7 days induced a 4-fold increase in CFC content and a 3- or 7-
fold improved engraftment at 4 or 7 weeks respectively in NOD-SCID mice compared with 
controls. This factor may activate the PI3-Kinase/AKT and Notch pathways by alleviating 
activation of its receptor, RPTP-/ (Himburg et al., 2010). 
3.2 Transcription factors: The HOX- family 
3.2.1 HOXB4 
The homeobox gene family member HoxB4 is the most investigated transcription factor for 
its potential to increase the self-renewal potential of HSC. HOXB4 belongs to a large family 
of transcription factors that share a highly conserved DNA-binding domain, the 
homeodomain. In mammals, there are 39 Hox genes grouped in four clusters referred to as 
A, B, C and D. In the hematopoietic system, 16 different Hox genes are transcribed during 
normal hematopoiesis. Primitive subpopulations express primarily genes of the A and B 
cluster (Giampaolo et al., 1995; Pineault et al., 2002; Sauvageau et al., 1994). Mice 
transplanted with marrow overexpressing HOXB4 resulted in a 47-fold increase of the 
competitive repopulating unit (CRU) numbers and did not develop leukemic transformation 
(Sauvageau et al., 1995). HOXB4 overexpression in mouse HSC cultured for 14 days induced 
a primitive cell-specific growth advantage contrary to a progressive depletion of HSC 
usually observed under these conditions. Total cell growth (mostly mature cells) was 
enhanced by 2-fold, progenitors by 3-fold and HSC by 1000-fold in cells overexpressing 
HOXB4 (Antonchuk et al., 2002).  
In humans, transient overexpression of HOXB4 in hematopoietic cord blood cells, did not 
increase proliferation of primitive progenitors, frequency of CFC, and LTC-ICs but induced 
an iincrease in myeloid differentiation (Brun et al., 2003). Other studies showed that 
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enforced high level of HOXB4 expression in human hematopoietic cord blood cells cultured 
for 24 hours induced a 5-10-fold increase in LTC-IC and a 4-fold increase in SRC (Buske et 
al., 2002). However, this HOXB4 overexpression markedly impaired the lymphoid and 
myeloerythroid differentiation (Schiedlmeier et al., 2003). Altogether these studies 
demonstrated that high levels of HOXB4 perturbed the myeloid differentiation program 
both in vivo and in vitro and are consistent with a dose dependant activity of HOXB4 to 
control the differentiation or self-renewal of HSC (Klump et al., 2005). 
To increase the effect of HOXB4, a NUP98-HOXB4 fusion gene was engeeniered since the 
fusion of Hox genes with the nucleoporine gene NUP98 is often reported in leukemia. Ohta 
et al. observed, in a murine transplantation model, a 300-fold increase in CRUs among 
NUP98-HOXB4-overexpressing cells compared to only 80-fold increase with HOXB4 alone. 
An even higher increase (2000-fold) was observed using the NUP98-HOXA10 fusion gene 
that, in contrast to HOXB4, blocks terminal differentiation and leads to a sustained output of 
cells with a “primitive” phenotype (Pineault et al., 2005; Pineault et al., 2004). The authors 
did not observe any long-term hematological defect in recipients repopulated with NUP98-
HOXA10 expanded HSC (Ohta et al., 2007). However, these results contrast with those 
obtained by Watts et al. in a nonhuman primate stem cell transplantation model. 
Transplantation of comparable doses of HOXB4- and NUP98-NUP98-HOXA10-
overexpressing cells revealed that HOXB4 contributed more to early hematopoiesis whereas 
NUP98-HOXA10 contributed more to later hematopoeisis. The emergence of a deleterious 
effect, such as leukaemia, could not be monitored due to the short survey period of the 
study (Watts et al., 2011). 
In 2006, Zhang et al. investigate the ability of HOXB4 to expand HSC in a clinically relevant 
nonhuman primate competitive repopulation model. They found an initial 56-fold 
advantage for the HOXB4-transduced cells which decline significantly over time (Zhang et 
al., 2006). In addition, the first appearence of myeloid leukemia linked to HOXB4 expression 
were observed two years later, both in the original group of monkeys (1 out of 2) and in 
dogs (2 out of 2) that received cells transduced with a HOXB4 expressing vector (Zhang et 
al., 2008b). None of the 40 dogs and monkeys that received cells transduced with control 
vectors developed leukemia. Besides, a profound growth inhibition and a rapid cell 
differentiation was induced by siRNA knocking down HOXB4 using a cell line derived from 
the leukemic cells of one animal. The direct implication of HOXB4 in the development of 
leukemia can not be certify since analysis of the vector insertion sites in the genome of all 
tumors revealed insertion of the transgene near or within protooncogenes, such as c-myb 
and PRDM16 (Zhang et al., 2008b).  
To avoid the use of retroviral vectors, Amsellem et al. generate an MS-5 stromal cell line 
secreting HOXB4 to expand human cord blood hematopoietic cells. Using a 5-week long 
term culture system, they show a 4-fold increase in LTC-IC and 2.5-fold increase in SRC in 
NOD-SCID mice. This expansion did not appear to interfere with myeloid or lymphoid 
differentiation. However, the coculture system might not be suitable for clinical applications 
(Amsellem et al., 2003). To avoid this issue, Krosl et al. used a soluble recombinant HOXB4 
protein fused to a small peptide derived from the HIV TAT protein. TAT-HOXB4 treatment 
of murine HSC for 4 days expanded approximately 4- to 6-fold and were 8-20 times more 
numerous than non treated HSC. This TAT-HOXB4 expanded population retained its 
normal in vivo potential for differentiation and long-term repopulation (Krosl et al., 2003). 
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The capacity of soluble HOXB4 to expand human HSC was verified using several 
recombinant human HOXB4 proteins. The N-terminal-tat and C-terminal histidine-tagged 
version of HOXB4 (T-HOXB4-H) had the highest activity in expanding CFC (10-fold) and 
LTC-IC (15-fold), and a 1.5- to 2.7-fold increase in SRC (Tang et al., 2009).  
3.2.2 Other HOX family proteins 
Surveys of Hox gene expression in HSC enriched populations showed dominancy of the 
HoxA cluster. In d14.5 fetal liver populations enriched for HSC, the expression of 
HOXA4 is a log higher than that of HOXB4. The fact that during this phase of 
development HSC undergo their major expansion, combined with the high homology 
and functional redundancy found within Hox paralog groups, suggests a putative role of 
HOXA4 to expand HSC with negligible or null oncogenic potential. HOXA4 
overexpressing HSC expanded 6.6-fold after a week of culture. Although HOXA4 
expressing HSC produced mature myeloid and lymphoid progeny in irradiated recipient 
mice, B-cell progenitors were preferentially expanded compared to myeloid progenitors 
(Fournier et al., 2011). 
HOXC4, another member of the Hox family, is also expressed in proliferating hematopoietic 
cells suggesting a role in the control of normal proliferation. Using retroviral gene transfer in 
human CD34+ cells, Daga et al. showed that HOXC4 induced an in vitro expansion of 
committed cells and early hematopoietic progenitors, with the most striking effect on LTC-
IC (13-fold expansion) (Daga et al., 2000). These results are consistent with those of 
Amsellem and Fichelson who showed a more efficient expansion of human CD34+/CD38low 
cells on MS-5 cell line secreting HOXC4 compared to those secreting HOXB4. The 
simultaneous presence of HOXB4 and HOXC4 seems synergize to improve expansion 
(Amsellem and Fichelson, 2006). However, the in vivo effect of HOXC4 still remains to be 
established. 
All these observations clearly implicated Hox family proteins in HSC self renewal but 
further studies are required to determine if the use of these compounds could be suitable for 
clinical applications. 
3.3 Chemical compounds 
The low efficiency obtained with purified proteins and the safety concerns when attempting 
to expand HSC with viral vector-mediated gene transfer (Baum et al., 2003) lead to 
searching for alternative and safer approaches. One of these promising strategies involved 
the use of chemical compounds.  
Chemical molecules constitute a particularly useful tool for modifying biological signaling 
pathways since they can be arrayed in chemical libraries for high-throughput analysis, 
and they can be withdrawn from the biological system once the desired effect is obtained. 
The use of a small molecule allows the study of the kinetics of a response in a more subtle 
and graduated way that is not possible with gene disruption techniques. These molecules 
may be further transposed into drugs for therapeutic use. Their use is rapid and cost-
effective. 
What are the sources of molecules available? 
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Historically, the pharmaceutical companies gathered the collections of molecules 
accumulated during the year in-house companies. These molecules can come from two 
different sources, one from natural origin and the other from chemically-synthesized 
compounds. Several companies have pooled their collections through partnerships to 
increase the size and diversity. At present, a large collection of oriented chemical libraries is 
available. In the milieu of academia, access to these collections is almost impossible unless a 
very restrictive partnership is framed. The number of screenable drug candidates have 
dramatically increased in the last years, and might account for 10 000 to 1 000 000 
compounds. The difficulty to use these large collections resides in the ability to order 
millions of natural products, many of which are available in only limited amounts and are 
not yet completely characterized or even purified. Further, to identify a molecule producing 
the desired biological effect, different concentrations covering several orders of magnitude 
should be initially screened. This is why their widespread use has not yet been generalized 
and most discoveries to date are mainly available through the pharmaceutical industry. 
During the past ten years, various companies have specialized in the provision of all-
purpose or targeted libraries. ChemBridge, ChemDiv, Asinex, Prestwick, Maybridge, 
enamine, Interbioscreen, TimTec can be mentioned as examples of commercially available 
collections. These libraries are relatively diverse and oriented "drug-like" (Kugawa et al., 
2007). Small-molecule compounds approved for use as drugs may also be "repurposed" for 
new indications and studied to determine the mechanisms of their beneficial and adverse 
effects. A comprehensive collection of all small-molecule drugs approved for human use 
would be invaluable for systematic repurposing across human diseases, particularly for rare 
and neglected diseases, for which the cost and time required for development of a new 
chemical entity are often prohibitive. Major efforts are now underway to produce 
comprehensive collections of these small molecules amenable to high-throughput screening 
(Huang et al., 2011). 
During the last ten years, cell-based phenotypic and pathway-specific screens using 
synthetic small molecules have provided new insights into stem cell biology and help to 
identify a number of small molecules that can be used to selectively (a) control self-renewal 
of embryonic and adult stem cells; (b) expand therapeutically desirable mature cell types; (c) 
control lineage commitment; and (d) enhance the reversion of lineage-restricted cells back to 
the multipotent or pluripotent state.  All four practices are beginning to find application in 
therapeutic settings. 
In this section we will focus on chemical compounds that were used to expand HSC. 
However, the most important question to keep in mind is whether the in vitro expanded 
cells preserve their capacities to regenerate hematopoiesis in vivo (Fig. 4). 
3.3.1 Chromatin-modifying agents 
Valproic acid (VPA) and chlamydocin are histone deacetylase (HDAC) inhibitors that exert 
their activity by interacting with the catalytic site of HDACs.  
VPA was first studied by De Felice et al. on human CD34+ cells isolated from cord blood, 
mobilized peripheral blood and BM. They showed that VPA preserves the CD34+ 
population after 1 week (40-89%) or 3 weeks (21-52%) of culture with cytokines and VPA 
increases H4 acetylation levels at specific sites on HOXB4 and AC133 (De Felice et al., 2005). 
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In 2008, using a two step culture system, Seet et al. showed that VPA induced a 2-fold 
expansion of human cord blood CD34+CD45+ cells. Higher numbers of treated cells resided 
in the S phase compare to controls. VPA-treated cells reconstituted hematopoiesis in NOD-
SCID mouse with a 6-fold higher efficiency compare to control cells. The advantage of using 
VPA resides on the fact that this molecule is clinically well-known since it has been used for 
more than 25 years to treat neurologic disorders (Seet et al., 2009). Chlamydocin, was 
showed to enhance Thy-1 expression on human CD34+ cells and to display a 4-fold increase 
in SRC in NOD-SCID (Young et al., 2004). 
 
Fig. 4. A diagrammatic representation of an experimental design typology to test the effect of 
molecules on HSC expansion.  Each molecule is added individually to the in vitro culture of 
HSC and the expansion capacities are then measured. However, infusion of the treated cells in 
myeloablated mice is essential to answer the question (?) on whether the HSC treated with the 
selected molecule have still the capacity to regenerate blood cells in transplanted animals.  
Another HDAC inhibitor, trichostatin A (TSA), and 5-aza-2’-deoxycytidine (5azaD), a DNA 
methyl transferase inhibitor where shown to act in synergy to yield a 12.5-fold increase of 
human CD34+CD90+ cells after 9 days of culture in comparison to the input cell numbers, a 
9.8-fold increase in the numbers of CFU and a 9.6-fold increase in SRC. Several genes 
implicated in HSC self-renewal including HOXB4, BMI1, GATA2, P21, and P27 were up-
regulated in the 5azaD/TSA-treated cells (Araki et al., 2006; Araki et al., 2007). 
3.3.2 Copper chelator tetraethylenepentamine (TEPA) 
Several clinical observations have suggested that copper plays a role in regulating HSC 
development. Peled et al. reported that modulation of cellular copper content might shift the 
balance between self-renewal and differentiation (Peled et al., 2005; Peled et al., 2002). This 
group cultured human CD34+ cord blood cells with the copper chelator TEPA during 
extended periods of time and showed a higher percentage of early progenitors (CD34+CD38-, 
CD34+CD38-Lin-) in the TEPA-treated cultures compared with controls and a 1- to 3-log-fold 
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expansion of CD34+ cells compare with that of controls. They cultured human CD133+ cord 
blood cells during 3 weeks, in order to use a clinically suitable protocol, and found that the 
median output value of CD34+ cells increased by 89-fold, CD34+CD38- by 30-fold and CFU by 
172-fold over the input values. Moreover, the CD34+ cells expanded with TEPA appeared to 
show improved NOD-SCID engraftment compare to control cells (Peled et al., 2004a; Peled et 
al., 2004b). Based on these data, a phase 1 trial was initiated. In this study, a portion of a single 
cord blood unit was cultured with TEPA and cytokines for 21 days and co-infused with the 
remainder of the untreated cell fraction. Although this methodology showed a 219-fold 
expansion of total nucleated cells in vitro, it did not improve the time to neutrophil or platelet 
recovery (de Lima et al., 2008). A phase 2/3 study is under way in more than 28 centers in the 
United States, Europe, and Israel, to evaluate the safety and efficacy of this approach 
(“StemEx”) in 100 patients with advanced hematologic malignancies 
(http://clinicaltrials.gov/ct2/show/NCT00469729). 
3.3.3 Oxygen, reactive oxygen species and antioxidants 
Low oxygen levels were also described to play a beneficial role on HSC expansion in vitro. 
This is consistent with the observation that protection of HSC in vivo is achieved by a 
predominantly low-oxygen environment of the stem-cell niche (Cipolleschi et al., 1993; 
Eliasson and Jonsson, 2010).         
The positive effect of hypoxia on the survival and/or self-renewal of the HSC population in 
vitro was demonstrated quantitatively on human marrow cells with Lin-CD34+CD38- 
phenotype which are enriched in SRC. A significant increase in SRC after 4 days was found 
in cultures under 1.5% O2 compared to normoxic conditions. The positive effect of hypoxia 
on SRCs is short-lived but their engraftment into immmunocompromised mice was to some 
extent improved (Danet et al., 2003). 
Similar studies have been performed with cord blood cells (Hermitte et al., 2006). The 
authors reported preferential survival of primitive HSC among cord blood CD34+ cells in 
cultures under 0.1% O2. After 72 hours, cells were 1.5 and 2.5 times more in quiescence (G0) 
at 3% and 0.1% O2. At 0.1% O2, 46.5%+/-19.1% of divided cells returned to G0 compared 
with 7.9%+/-0.3% at 20%. This shows a return of the cycling CD34+ cells into G0, a quiescent 
state that characterizes steady-state HSC.  
During the process of HSC purification or mobilization from the BM to the peripheral blood, 
the cells go across different levels of oxygenation until reach maxima in culture assays. 
Furthermore, cell factors added to these cultures can lead to an abnormal increase in 
reactive oxygen species (ROS) in the HSC and to a ROS stress that might change their 
properties and functions (Hao et al., 2011; Ito et al., 2006; Pervaiz et al., 2009). These ROS are 
unstable reactive molecular species possessing an unpaired electron that are produced 
continuously in cells as a byproduct of metabolism. They participate in vital signal 
transduction pathways but they can also oxidize DNA, proteins, and lipids leading to cell 
differentiation, senescence, and apoptosis. Notably, the mouse long-term repopulating HSC 
capacities were found in a Roslow population (Jang and Sharkis, 2007). This cell population 
has a higher self-renewal activity than a Roshigh population both in vitro and in vivo. 
Moreover, distinct metabolic profiles of HSC reflect their location in the hypoxic niche 
(Simsek et al., 2010; Takubo et al., 2010). 
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The continual production of ROS in the in vitro culture (Iiyama et al., 2006) might be 
overcome by the addition of antioxidants. These molecules will maintain the ROS at a low 
level, thereby regulating the proliferation, growth, signal transduction, and gene expression 
of the cells (Chen et al., 2008).  
Antioxidants are classified into enzyme and non-enzyme antioxidants. Enzyme antioxidants 
include superoxide dismutase, catalase, and glutathione peroxidase. Non-enzyme 
antioxidant includes vitamin C.  
The application of enzyme antioxidants is limited because of the poor stability and ease of 
inactivation (Wojcik et al., 2010). However, when culturing mouse HSC in the presence of 
catalase, the number of short-term or long-term HSC with LSK immune markers was 
significantly increased and the stem cells begin to degenerate as the catalase is removed  
(Gupta et al., 2006). 
Ascorbic acid (vitamin C) is a natural water-soluble antioxidant but under some 
conditions such as the air, heat, light, alkaline substances, enzymes and trace amount of 
copper oxide and iron, oxidation of vitamin C could be accelerated and the oxidative 
products lead to the damage of cellular DNA. The ascorbic acid 2-phosphate (AA2P), one 
derivative of vitamin C, is stable at 37°C in cell culture media and has no cytotoxic effect; 
therefore it might constitute an advantageous antioxidant (Duarte et al., 2009). Reducing 
oxidative stress by N-acetyl-L-cysteine (NAC) may enhance the viability and engraftment 
of HSC as  treatment of gene corrected BM mononuclear cells or purified CD34(+) cells 
from FANCA patients  with the reducing agent NAC showed increased CFC (Becker et 
al., 2010). 
Although the current amplification under normal oxygen can expand a certain number of 
HSC, the application of glutathione for stem cell mobilization and re-infusion as well as the 
application of AA2P in the in vitro amplification culture of cells may become effective 
methods for protecting the hematopoietic reconstitution capacity of HSC (Hao et al., 2011). 
Moreover, in vitro culturing HSC-enriched samples under O2 concentrations that more 
closely resemble the BM environment (low O2 concentrations, 1–3%) might also improve 
their expansion and preserve proper stem cell functions for engraftment.  
3.3.4 PGE2 
Prostaglandin E2 (PGE2) was first identified as capable of enhancing HSC formation in 
zebrafish, following a high-toughput chemical screen. This effect was also tested using 
murine transplantation assays. When murine BM cells where briefly treated ex vivo by 
PGE2, a 3-fold increase in the CFU number and a 3.3-fold increase of SRC 6 weeks post 
transplantation were observed (North et al., 2007). Hoggatt et al. confirmed enhanced 
murine HSC engraftment following PGE2 exposure as they observed a 4-fold increase in 
HSC 20 weeks after transplantation. The increase in chimerism was still present in 
primary recipient 32 weeks post-transplant and in secondary recipients without 
additional PGE2 treatment. Several studies were performed to determine whether the 
action of PGE2 on HSC could be the result of an increase in HSC numbers, homing 
capability, proliferation, survival, or a combination thereof. Hoggatt et al. observed a 
significant increase in homing of PGE2-treated LSK cells. This was partially attributed to 
an increase in CXCR4 expression, a SDF1ǂ specific receptor. This effect also occurs in 
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human HSC, since PGE2-treated cord blood cells transplanted into NOD-SCID mice 
displayed an enhanced homing to marrow. In addition, PGE2 treatment increased 
survivin expression, reduced intracellular active caspase-3 that lead to enhanced HSC 
survival and increased the percentage of cycling cells (Hoggatt et al., 2009). Frish et al. 
treated mice in vivo with PGE2 by intraperitoneal injection twice a day for 16 days. They 
observed a significant increase of the LSK population without inhibiting their 
differentiation. The treatment expands preferentially the short-term-HSC/MPP 
subpopulation since this advantage was lost 6 weeks post-transplant in primary 
recipients and in secondary transplants. The disparities between these studies may be the 
result of the extended exposure of mice to PGE2 compared with a short term pulse used 
hitherto (Frisch et al., 2009).  
Goessling et al. briefly treated human cord blood CD34+ cells in vitro with dimethyl-PGE2 
(dmPGE2). They showed that dmPGE2 treatment decreased apoptosis, increased 1.4-fold 
the CFU number and enhanced engraftment of unfractionated and CD34+ cord blood cells 
after xenotransplantation in NOD-SCID mice. Using a non-human primate transplantation 
model, they found no significant enhancement of CD34+-treated cells engraftment but 
showed that dmPGE2 treatment had no negative impact on HSC function, including 
multilineage repopulation, even 1 year post-transplantation. They suggested that these 
results reflect suboptimal compound dosing and anticipate the use of 50µM rather than 
10µM of dmPGE2 in future transplantation assays (Goessling et al., 2011). Based on these 
data, this brief ex vivo incubation with dmPGE2 is currently being tested in a phase 1 clinical 
trial in which adults with hematologic malignancies receive a non-myeloablative 
conditioning treatment followed by double-unit cord blood transplantation in which 1 of the 
2 cord blood units has been incubated with dmPGE2 before infusion 
(http://clinicaltrials.gov/ct2/show/ NCT00890500). 
3.3.5 Aryl Hydrocarbon receptor (AhR) antagonists  
Using a high-throughput screen based on CD34/CD133 expression, Boitano et al 
identified a purine derivative (StemRegenin1 or SR1) capable of in vitro enhancing the 
levels of a CD34+ cell population derived from blood of mobilized donors. SR1 added to 
human CD34+ cells cultured for 5 weeks led to a 10-fold increase in total nucleated cells, a 
47-fold increase in CD34+ cells and a 65-fold increase in CFU. CD34+ cord blood cells 
cultured in the presence of SR1 for 3 weeks revealed a 17-fold increase in SRC content in 
NOD-SCID Gamma (NSG) primary recipient and a 12-fold increase in the number of 
secondary SRC compared to input (Boitano et al., 2010). Additional screens followed by a 
quantitative structure-activity relationship identified three novel compounds (i.e SR2, SR3 
and SR4), structurally distinct from SR1, that expand the number of human CD34+ cells. 
Experiments that aimed to determine the ability of cord blood derived human HSC 
expanded with these molecules to engraft NSG mice are still undergoing (Bouchez et al., 
2011). SR1, SR2, SR3 and SR4 were showed to act as antagonists of AhR signaling. Indeed, 
this receptor has been implicated in HSC biology and hematopoietic disease through 
numerous factors including c-MYC, HES-1, PU.1, C/EBP, -catenin, CXCR4, and STAT-5 
(Singh et al., 2009). However, the precise mechanism whereby an AhR inhibitor might 
induce HSC self-renewal remains unknown. 
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The transcription factor SALL4 was reported to play a role in maintaining ES cell 
pluripotency through interaction with Oct4 and Nanog (Wu et al., 2006; Yang et al., 2010). It 
was recently showed that overexpression of SALL4 can expand ex vivo human mobilized 
HSC from peripheral blood (Aguila et al., 2011). SALL4-transduced cells seemed capable of 
ex vivo expansion of both, CD34+CD38- and CD34+CD38+ cells and showed enhanced stem 
cell engraftment and long term repopulation capacity in NOD-SCID mice. Moreover, human 
CD34+ cells cultured 3 to 4 days with a soluble SALL4 fusion protein (TAT-SALL4B) showed 
a 10-fold increase in total mononuclear cells, a 8-fold increase in CD34+ cells and a 10-fold 
increase in the CFU number compare to controls (Aguila et al., 2011). However, in vivo 
studies with this fusion protein still have to be conducted to validate that these expanded 
cells are still able to reconstitute hematopoiesis in transplanted recipients. 
4. De novo generation of HSC 
Considering the interest in HSC expansion for treatment of both malignant and non-
malignant diseases as well as their use in gene therapy and the difficulty to obtain ex vivo 
expansion of HSC without loss of their regeneration capacities, relevant methods to produce 
de novo HSC have emerged.  
4.1 Obtaining HSC from ESC 
One of these methods was initiated 20 years ago when ESC could be cultivated in vitro and 
directed to generate hematopoietic cells (Wiles and Keller, 1991). Since then, culture 
conditions were constantly optimized and allowed the differentiation into specific 
hematopoietic lineages such as erythroid and myeloid lineages, T and B lymphocytes and 
megakaryocytes (for review see Sakamoto et al., 2010). These protocols were then adapted to 
human (h) ESC. These cells like their murine counterparts, are karyotypically stable, capable 
of prolonged self-renewal, and might differentiate into most cell types. These properties 
might be exploited for therapeutic benefits to cure many human degenerative diseases and 
resulted in intense biomedical studies.  
Different methods were established to generate hematopoietic progenitors and specific 
lineages from mouse ESC including embryoid bodies formation, coculture with stromal 
cells, and direct differentiation in coated plates using a mixture of cytokines and growth 
factors without stromal cells (Tian and Kaufman, 2008). These protocols were then 
optimized for efficient differentiation of hESC into early mesodermal cells (Bernardo et al., 
2011) and for obtaining defined hematopoietic precursors from ES cells (Chiang and Wong, 
2011; Salvagiotto et al., 2011).  
The ultimate goal of these strategies is to produce HSC capable of robust, long-term, 
multilineage engraftment to alleviate blood cells diseases; however the numbers and the 
capacities of the de novo cells generated are not quite sufficient to fulfill the clinical 
challenge. At present, multipotent hematopoietic progenitors (short-term HSC) with limited 
engrafting ability in transplanted mice were obtained (Woods et al., 2011). Other groups 
reported efficient generation of cells that mostly produce the myeloid lineage following long 
term engraftment or produce CD34+ hematopoietic precursors that have phenotype similar 
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to adult HSC but might best correspond to the embryonic stage of yolk-sac, aortogonadal- 
mesonephros (AGM), and/or fetal liver stage of hematopoiesis (Melichar et al., 2011; 
Narayan et al., 2006 and for review : Tian and Kaufman, 2008). More recently, the polycomb 
group protein Bmi1 was shown to promote more than 100-fold increase of hematopoietic 
cell development from ESC (Ding et al., 2011). 
Since short-term HSC could be generated from ESC, an attractive option to increase the 
number of clinically competent HSC would be to find a molecule that dedifferentiate from 
short-term or mature hematopoietic cells to the long-term HSC population. Such a strategy 
might be valuable, since de-differentiation of somatic cells mediated by a chemical has been 
achieved in other systems. This is the case for reversine or 2-(4-morpholinoanilino)-6-cyclo-
hexylaminopurine. This chemical compound was reported to induce reversal of mouse 
myoblast cell line, C2C12, to become multipotent progenitor cells, which can re-differentiate 
into osteoblasts and adipocytes (Chen et al., 2004). The de-differentiation activity of 
reversine however is not conserved across all cell lineages, since in certain cell types, it acts 
as a potent differentiation-inducing molecule (D'Alise et al., 2008). 
To support the generation of long-term repopulating HSC from mouse ESC, other groups 
tested intrinsic regulators of adult HSC (Schuringa et al., 2004; Wang et al., 2005b). 
However, the use of many of these compounds, such as HoxB4, did not improve the 
expected engraftment efficiency in vivo (Wang et al., 2005a). 
An unfavorable complication for the use of ESC in producing HSC is that lifelong use of 
drugs is required to prevent rejection of the transplanted cells. In order to make ESC 
practical for therapeutic use, it would be necessary to create a new stem cell line for each 
patient that needs treatment. Serious technical and ethical problems are associated with this 
issue. 
4.2 Obtaining HSC from induced pluripotent stem cells 
An alternative to the utilization of ES cells to produce de novo HSC arise from one of the 
most transformative accomplishments performed in the last years: the discovery that 
transient overexpression of a small number of defined transcription factors can reprogram 
the differentiated cells and become pluripotent populations. These cells are commonly 
referred to as Induced Pluripotent Stem Cells (iPSC) and have definitively broken the 
dogma commonly accepted that differentiated cell types generally lack the ability to revert 
back to a less specialized state. 
4.2.1 Reprogramming somatic cells to pluripotency 
The direct reprogramming of somatic cells to pluripotency was demonstrated in 2006, when 
Takahashi and Yamanaka converted adult mouse fibroblasts to iPSC by overexpressing four 
transcription factors: octamer-binding transcription factor 4 (OCT4), sex determining region 
Y-box 2 (SOX2), Kruppel-like factor 4 (KLF4), and cytoplasmic Myc (c-MYC) in mouse 
embryonic fibroblasts using retroviruses (Takahashi and Yamanaka, 2006). The transcription 
factors originally used for reprogramming differentiated cells are not stringently necessary 
to achieve this process as some of them can be replaced by other factors. Yu et al. were able 
to reprogram human fibroblasts with a distinct set of transcription factors comprising OCT4, 
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SOX2, NANOG, and LIN28 (Yu et al., 2007). Krüppel-like transcription factors (Klf2 and 
Klf5) and the orphan nuclear receptor, Esrrb, can replace Klf4 (Nakagawa et al., 2008 and for 
review see Feng et al., 2009). 
The derived iPSC exhibited typical ESC morphology and were similar to ESC in their 
regenerative potential (Takahashi and Yamanaka, 2006) and their capacity to differentiate 
into cells of all three germ layers, the ectoderm, mesoderm, and endoderm. Because iPSC are 
generated without the need to destroy an embryo, their discovery has further energized the 
field of regenerative medicine and stem cell biology. Patient-specific therapeutic cells 
derived from induced pluripotent stem iPSC may bypass the ethical issues associated with 
ESC and avoid potential immunological reactions associated with allogenic transplantation. 
These human disease–specific iPSC provide a unique and previously unavailable resource 
for studying the pathophysiology of various important human diseases. 
The therapeutical hope of iPSC is based on three issues: 1) The ability to generate iPSC from 
any tissue of the organism, and further differentiate them according to the patient needs, 
particularly into a wide range of primary human cell types, many of which are unavailable 
for routine use;  2) The ability to generate iPSC from patients with any disease; 3) The 
possibility of using patient-derived iPSC for drug development.  
The therapeutic potential of such iPSC (schematized in Fig. 5) was demonstrated in a proof-
of-principle study using a humanized sickle cell anemia mouse model (Hanna et al., 2007). 
In this study, mice could be rescued after transplantation with hematopoietic progenitors 
obtained in vitro from autologous iPSC. This was achieved after correction of the human 
sickle hemoglobin allele by gene-specific targeting.  
 
Fig. 5. Studies performed to validate the therapeutic potential of iPSC. 
Also in mice, Xu et al. cured hemophilia by transplantation of cells that were generated from 
murine wild-type iPSC. These murine experiments suggest that human iPSC can be utilized 
for regenerative and therapeutic applications  (Xu et al., 2009). Most recently, patient-
specific iPSC have been established. Raya et al. reprogrammed dermal fibroblasts and/or 
epidermal keratinocytes of Fanconi anemia patients to generate iPSC, which were 
genetically corrected with lentiviral vectors encoding FANCA or FANCD2, to obtain 
hematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically 
normal, that is, disease-free (Raya et al., 2009). Similar strategies were performed to correct 
the Hurler syndrome (Tolar et al., 2011) and for the production of macrophages from iPSCs 
which were resistant to HIV infection (Kambal et al., 2011). 
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The enthusiasm surrounding the clinical potential of iPSC is tempered by key issues 
regarding their safety, efficacy, and long-term benefits. Fully realizing the biomedical 
potential of iPSC in a clinical setting will require addressing certain limitations inherent to 
the process. First, need to find alternative strategies to remove non-viral or non-integrative 
vectors to overcome their potential deleterious effects. Although expression of the 
exogenous reprogramming factors is eventually silenced during iPSC cell generation, there 
is a significant risk of tumorigenesis if these exogenous genes are inadvertently reactivated. 
Second, it will be essential to increase the number of cells with specific phenotype. Third, it 
will be necessary to improve the efficiency of reprogramming (0.001–3% of cells are 
reprogrammed) since this is a slow and inefficient process (Jaenisch and Young, 2008; 
Nakagawa et al., 2008; Wernig et al., 2008). 
4.2.2 Improving reprogramming somatic cells to pluripotency 
To overcome the potential deleterious effects of viral vectors or oncogenes, and to 
improve the efficiency of the process toward a potential clinical application, a powerful 
alternative is offered by using small molecules. Several small molecules were reported to 
improve the reprogramming process by lowering the epigenetic barrier to initiate 
pluripotency (for reviews see Feng et al., 2009; Lyssiotis et al., 2011). Consistent with this 
notion, small molecules that affect reorganization of chromatin architecture, a rate 
limiting step during the reprogramming of a somatic genome, have been identified 
(Blelloch et al., 2006; Hochedlinger and Jaenisch, 2006; Huangfu et al., 2008a). In 
particular, the HDAC inhibitor VPA was shown to strongly increase reprogramming 
efficiency in the absence of c-Myc in both mouse and human cells and to allow 2-factor 
reprogramming (Oct4 and Sox2) of human fibroblasts in the absence of Klf4 and c-Myc 
(Huangfu et al., 2008b). Other epigenetic regulators such as BIX01294, a G9a histone 
methyltransferase inhibitor; BayK8644, an L-type calcium channel agonist and the two 
DNA methyltransferase inhibitors, AzaC and RG108 (summarized  in Fig. 6), 
substantially increased reprogramming efficiency  (Lukaszewicz et al., 2010; Shi et al., 
2008).  
The low efficiency of reprogramming (Hong et al., 2009) might also result from the 
accumulation of ROS (Parrinello et al., 2003). Consistent with this, Esteban et al. found that 
vitamin C strongly increases the reprogramming efficiency (Esteban et al., 2010). This is in 
line with the study reporting that hypoxic conditions improve the efficiency of iPSC 
production generated from mouse or human somatic cells (Yoshida et al., 2009). Co-
treatment with VPA synergizes this effect. Other molecules including the MEK inhibitor 
PD0325901, the GSK3 inhibitor CHIR99021 combined with tranylcypromine, kenpaullone, 
SB-431542, and the TGF- signaling inhibitor called RepSox (Ichida et al., 2009) were 
reported to enhance reprogramming or to replace viral vectors or oncogenes (Li and Ding, 
2009; Pan and Thomson, 2007).   
With the continued use of high-throughput screening to identify more chemicals that could 
assist in reprogramming, we may be closer to the goal of using a chemical-only cocktail to 
reprogram somatic cells to iPSC. These pluripotency gene activators may be then used in 
combination with specific differentiation modulators to achieve the production of the 
desired cell type. 
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Fig. 6. Chemicals used to enhance reprogramming or to replace core reprogramming 
factors. 
4.2.3 Obtaining HSC from induced pluripotent stem cells  
Differentiation of iPSC into hematopoietic lineage have been achieved using a 
combination of specific cytokines and growth factors (Sakamoto et al., 2010) and have 
already demonstrated from both mouse and human iPSC (Lengerke et al., 2009; Niwa et 
al., 2009; Woods et al., 2011). However, the number of cells obtained in view of 
therapeutic use is still insufficient and small molecules that might expand the production 
of hematopoietic cells have yet to be found. Studies in this direction are beginning to 
emerge. For example, Wnt signaling, in particular WNT3a, mediates the stimulation of 
hemoangiogenic cell development and increase hematopoietic differentiation from ESC 
and iPSC (Wang and Nakayama, 2009; Wang et al., 2010). However, the conditions to 
generate human HSC capable of robust, long-term, multilineage engraftment from iPSC 
are still hoped for. 
5. Conclusion 
The ex-vivo expansion of HSC represents a promising approach to obtain large enough 
quantities for therapeutic intervention in cell and gene therapy protocols. Derivatives of 
hESCs and iPS cells are also expected to be employed as de novo HSC source for therapeutic 
settings. However, as described in the previous section, practical and ethical issues must be 
settled before clinical practice can begin. In both cases, the chemical biology approach using 
small molecules as tools or drugs holds unquestionably greater promise in the outcome of 
the final goal. 
Even though a few molecules are being tested in clinical assays, the ideal soluble factor that 
enables to increase the number of rare HSC during the ex vivo growth culture without 
limiting their regeneration capacities has yet to be found. Most attempts have been 
unsuccessful because i) suitable expansion in vitro has been mostly correlated with loss of 
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the regenerative capacities of HSC in vivo; ii) no straight forward method allows the 
association of in vitro observations with the in vivo outcome; iii) testing the in vivo effect of 
each molecule independently would be costly, time-consuming and would need an 
imposing number of mice which is ethically inconceivable.  
In an attempt to develop new tools that might overcome some of these limitations, we have 
developed an innovative screening strategy to identify molecules for their potential to 
improve the in vitro HSC self-renewal and proliferation while preserving the HSC 
regenerative capacities in vivo (Sii Felice K, Grosselin J, Leboulch P, Tronik-Le Roux D, 
manuscript in preparation). Our approach is based on stem cells labeling with specific 
barcodes before exposure to the molecules (Fig. 7).  Then, prior to their infusion in 
myeloablated mice, all the treated cells are pooled. Several weeks after transplantation, the 
identification of barcodes present in the blood and the BM of transplanted mice will enable 
the precise retrospective quantification of the initial effect of the molecule.  
 
Fig. 7. Schematic representation of the strategy developed to simultaneously test dozens of 
molecules. Each well contains barcoded-HSC (1) treated by a particular molecule. After 
several days of in vitro culture (2), all the cells are pooled, infused in myeloablated mice. The 
identification of barcodes in blood and BM of transplanted mice will enable the precise 
retrospective quantification of the initial effect of the molecule.   
This strategy might facilitate the development of high-throughput screening for fast and 
effective identification of small molecules that can be used to burst the production of HSC. 
This will undoubtedly accelerate the promise of regenerative medicine as a routine 
therapeutic modality for many blood diseases as well as for gene and cell therapy. 
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